Hydrocephalus Market Research Report: Information by Type (Congenital Hydrocephalus, Acquired Hydrocephalus, Normal-Pressure Hydrocephalus, Ex-Vacuo Hydrocephalus), Diagnostic (CT scan – head, MRI, Head Ultrasound), Treatment (Surgery – Shunt Insertion, Ventriculostomy, Medication), End User (Hospitals & Clinics, Diagnostic Centres, Academic Institutions and Research Organizations) and Region - Global Forecast till 2027
ID: MRFR/MED/1187-CR | August 2019 | Region: Global | 139 pages
Market Scenario:
The Global Hydrocephalus Market is growing at a healthy pace and is expected to be USD 1,348.00 million in 2017, at a CAGR of 4.4% during the forecast period 2018-2023.
Hydrocephalus is a condition that characterized by buildup of cerebrospinal fluid (CSF) in the brain cavities (ventricles). The ventricles expand as a result of fluid accumulation, causing an abnormal increase in brain size. In normal conditions, the cerebrospinal fluid usually flows through the cavities of the brain and spinal column, but in hydrocephalus, the excessive CSF accumulation causes damage to the brain tissues, leading to a number of brain impairments. This condition can occur in any age, but it is more prevalent in infants and older adults. The increasing prevalence of hydrocephalus is directly responsible for the market growth. The major cause for this condition in children is found to be malnourishment of the fetus. this condition is mostly genetic however, it can also manifest in adults and is known as acquired hydrocephalus.
Shunting is a primary line of treatment for hydrocephalus. Shunting creates a bypass for the accumulated fluid to flow to other parts of the body. The increasing prevalence of traumatic brain injuries due to accidents and shifting patient preference towards minimally invasive surgeries in geriatric population are considered as the key factors that are projected to encourage the growth of the global hydrocephalus market in the coming years. In addition to this, the growing disposable income among consumers and the rapid development in the healthcare infrastructure are further predicted to enhance the growth of the overall market in the next few years.
Market Dynamics
The market for hydrocephalus is not very well developed due to lack of attention paid to the treatment of the disease. Following the development of shunts for draining the accumulated cerebrospinal fluid and scans to diagnose this condition, there have been improvements in terms of treatments to provide short-term relief to patients. However, there are efforts to develop treatments to address the disease at initial stages and this has ensured a positive growth trend for the market.
Further, Posttraumatic hydrocephalus (PTH) is a recurrent and serious complication that follows a traumatic brain injury (TBI). The prevalence of this condition varies greatly based on different criteria for its diagnosis. It can be caused by the blockage of normal cerebrospinal fluid (CSF) flow, overproduction of CSF, or insufficient absorption that result in excessive accumulation of CSF around the brain
The use of ICP devices is for measuring the fluid pressure within the brain which may be caused by trauma or other conditions. ICP monitoring has a significant importance in diagnostic and post-operative procedures with cranial injury as seen in cases of stroke, hydrocephalus, and trauma. According to the estimate of the Centers for Disease Control and Prevention (CDC) in 2017, more than 1.75 million traumatic brain injuries occur in North America, annually and these monitoring devices enable surgeons to save lives of patients with timely intervention and treatment. The increasing accidental cases causing traumatic brain injuries are going to act as drivers for the hydrocephalus market.
Figure 1: - Global Hydrocephalus Share, by Region 2017 (%) 
Sources: WHO, Centers for Medicare & Medicaid Services, Annual Reports, Press Release, White Paper, and Company Presentation
Segmentation
The global Hydrocephalus market is segmented on the basis of type, diagnostic, treatment, end user. On the basis the type, the market is segmented into congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, ex-vacuo hydrocephalus. on the basis of the diagnostic, the market is segmented into CT scan – head, MRI, head ultrasound. on the basis of treatment, it is segmented into surgery – shunt insertion, ventriculostomy, medication. on the basis of end user, it is segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations
Regional Analysis
The global market for hydrocephalus is segmented on the basis of regions into Americas, Europe, Asia Pacific, and Middle East & Africa.
The Americas held the largest share of the global hydrocephalus market owing to the rising prevalence of hydrocephalus, the presence of a well-developed healthcare sector, and the major market players. The continuous increase in the number of Americans affected from hydrocephalus coupled with ongoing research in neuroscience aid to the market growth. On a regional basis, the Americas is divided into North America and South America. North America is estimated to lead due to the presence of developed economies such as the US and Canada within the region. South America, however, is estimated to have the faster growth.
Europe stands second in the global market due to the constant evaluation of various techniques by neurosurgeons for the improvement of hydrocephalus management, is expected to drive growth in this market. Moreover, shunt manufacturers are engaged in investment for development of novel and improved shunts in order to tackle the pitfalls associated with the existing designs. The child population, aging in between 0 and 14 years, is estimated to increase from 17.6% of the total population in 2013 to 18.4% of the total population by 2020. This provides favorable background for market growth in Europe.
Key Players for the Global Hydrocephalus
Some of the key players in this market are DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc, Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services Inc, B. Braun Melsungen AG, Christoph Miethke GmbH & Co. KG, Tokibo Co., Ltd, HLL Lifecare Limited and others
- September 2017 Natus Medical Incorporated acquired neurosurgery business assets from Integra LifeSciences, thus entering into the neurosurgery business segment
- October 2017 Integra Lifesciences acquired Codman Neuro from Johnson & Johnson for USD 1.1 billion. Integra is divesting its assets in order to get FTC's permission on its proposed acquisition of Johnson & Johnson's Codman Neurosurgery business. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neurointensive care, and cranial surgery, and generated net revenues of approximately USD 371.5 million in 2016.
Market Segmentation
Global Hydrocephalus, by Type
- Congenital hydrocephalus
- Acquired hydrocephalus
- Normal-pressure hydrocephalus
- Ex-vacuo hydrocephalus
Global Hydrocephalus, by Diagnostic
- CT scan – head
- MRI
- Head Ultrasound
Global Hydrocephalus, by Treatment
- Surgery – Shunt Insertion
- Ventriculostomy
- Medication
Global Hydrocephalus, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Academic Institutions and Research Organizations
Intended Audience
- Pharmaceutical Companies
- Hospitals
- Research and Development (R&D) Companies/Laboratories
- Market Research and Consulting Service Providers
- Potential Investors
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 4.4% (2018-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnostic, Treatment, End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc, Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services Inc, B. Braun Melsungen AG, Christoph Miethke GmbH & Co. KG, Tokibo Co., Ltd, HLL Lifecare Limited and others |
| Key Market Opportunities | Investments in development of new shunts |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The hydrocephalus market valuation was USD 1348 million in 2017.
The projected CAGR would be 4.4% for the forecast period.
The end users are diagnostic centers, hospitals & clinics, academic institutions & research organizations.
The segments are MRI, CT scan – head, and head ultrasound.
America is leading the hydrocephalus market.
Global Hydrocephalus Market - Summary
Overview
Hydrocephalus is medical condition in which excess levels of cerebrospinal fluid (CSF) in the ventricles can increase the intracranial pressure in the brain. This condition in noticeable in infants and older adults. Infants are likely to attain this disorder either due to genetics or malnourishment in the fetal stage.
The global hydrocephalus market is expected to reach a valuation of USD 1,752.07 million by 2023 at a CAGR of 4.4% from 2018 to 2023 (forecast period). The exponential growth is credited to increasing incidence of traumatic brain injuries (TBI). According to the Centers for Disease Control & Prevention (CDC), nearly 1.75 million cases of TBI occurred in 2017. Continuous development of shunts and other equipment for increasing the success of hydrocephalus surgeries is likely to boost market demand.
Favorable medical reimbursement schemes which cover treatment costs can provide the hydrocephalus market the required tailwind. This is backed by inflated healthcare expenditure of nations in the Gulf Cooperation Council (GCC) and others. High prevalence of neurological conditions such as brain aneurysm can further the market growth as well. According to the Brain Aneurysm Foundation, the condition has been responsible for causing 500,000 deaths worldwide annually. Moreover, medical reimbursement schemes covering brain aneurysm treatment such as stents can bode well for the market.
Industry Opportunities
Intraoperative neurophysiological monitoring (IONM) are an array of methods designed to check the functions of nerves during surgery. Emergence of medical institutions which are offering courses to medical professionals for upskilling is likely to bode well for the market. In addition, technological breakthroughs in the form of endovascular embolization and wire micro-guide catheters which can provide a pathway to the brain. Both procedures offer good outcomes with low amount of medical complications.
Segmentation
Types include acquired hydrocephalus, congenital hydrocephalus, ex-vacuo hydrocephalus, and normal-pressure hydrocephalus (NPH). Congenital hydrocephalus dominated the hydrocephalus market in 2017 owing to the condition being prevalent in neonates. It can exhibit a strong growth rate over the forecast period due to efforts by nations to lower the mortality rate caused by the neurological condition. But the NPH segment is expected to exhibit an impressive CAGR owing to its high prevalence in patients above the age of 60.
Methods of diagnosis for the medical condition in the hydrocephalus market include MRI, head ultrasound, and CT scan-head. MRI remains the most trustworthy method and will exhibit the highest CAGR in the market till 2023. The technology can scan accurate images of the brain to discern the presence of malformations. This can be used to detect hydrocephalus and other neurological or neurovascular conditions.
By treatment, the market is segmented into medication, ventriculostomy, and surgery-shunt insertion. The surgery-shunt insertion segment can exhibit an impressive CAGR during the forecast period owing to the improvement shown in draining the excess levels of CSF. Ventriculostomy can display an impressive growth rate owing to extensive application of ventricle shunts used for creating a path for CSF to exit.
End-users in the hydrocephalus market include hospitals & clinics, research institutes & academic centers, and diagnostic centers. Hospitals & clinics can generate significant revenue for the market owing to the institution equipped with intracranial pressure (ICP) monitors. High prevalence of TBI being treated by surgeons at hospitals with high success outcomes can augur well for the segment. But diagnostic centers can display the strongest growth rate owing to the need for high-resolution procedures to detect abnormalities in brain ventricles at an early stage.
Regional Analysis
Geographic segmentation of the hydrocephalus market comprises Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas held the highest market share in 2017 owing to high prevalence of neurological conditions, sophisticated healthcare infrastructure, and presence of major players. On the other hand, APAC can display the highest growth rate owing to rapid growth of China and India and their large patient pool. Government support in form of funding to expedite research and development in shunts and other imaging technologies can drive the regional hydrocephalus market till 2023.
Competitive Landscape
Key players in the hydrocephalus market include HLL Lifecare Limited (India), Integra LifeSciences Corporation (U.S.), Johnson & Johnson Services Inc. (U.S.), Natus Medical Incorporated (U.S.), B. Braun Melsungen AG (Germany), Boston Neurosciences (U.S.), Terumo Corporation (U.S.), Medtronic Plc (Ireland), Spiegelberg GmbH & Co. KG (Germany), Sophysa SA (France), RAUMEDIC Inc. (Germany), DePuy Synthes (U.S.), Christoph Miethke GmbH & Co. KG (Germany), and Tokibo Co., Ltd. (Japan).
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Scope of Study 20
3.2 Research Objective 20
3.3 List of Assumptions 21
3.4 Market Structure 21
4 Research Methodology
4.1 Research Process 23
4.2 Primary Research 24
4.3 Secondary Research 25
4.4 Market Size Estimation 26
4.5 Forecast Model 26
5 Market Dynamics
5.1 Introduction 28
5.2 Drivers 29
5.2.1 Growing Prevalence of Traumatic Brain Injuries 29
5.2.2 Ongoing Product Development & Commercialization Will Boost the Adoption of Hydrocephalus Shunts in the Market 29
5.2.3 Favorable Reimbursement Policies Provide Favorable Background for the Market Growth 29
5.2.4 Increasing Prevalence of Neurovascular Diseases such as Brain Aneurysm, Arteriovenous Malformations (AVMs),
and Others, are Likely to Propel the Hydrocephalus Market 30
5.3 Restraints 31
5.3.1 High Procedural Cost of ICP Monitoring Devices 31
5.3.2 Shortage of Trained Professionals 31
5.4 Opportunities 32
5.4.1 Increase in Awareness of Intraoperative Neurophysiological Monitoring (IONM) 32
5.4.2 Increasing Use of Endovascular Embolization for the Treatment of Brain Aneurysm 32
5.4.3 Technological Advancements in Over the Wire Micro Guide Catheters 32
5.5 Challenges 33
5.5.1 Rising Partnership Among Competitors Leading to Rivalry 33
5.6 Changing Economic Conditions Globally 33
6 Market Factor Analysis
6.1 Porter’s Five Forces Model 35
6.1.1 Bargaining Power of Suppliers 35
6.1.2 Bargaining Power of Buyers 36
6.1.3 Threat of New Entrants 36
6.1.4 Threat of Substitutes 36
6.1.5 Intense Rivalry 36
6.2 Value chain analysis 37
6.2.1 R&D 37
6.2.2 Manufacturing 37
6.2.3 Distribution & Sales 37
6.2.4 Post-Sales Monitoring 37
6.3 Investment Opportunities 38
7 Hydrocephalus Market, by Type
7.1 Introduction 40
7.1.1 Congenital Hydrocephalus 41
7.1.2 Acquired Hydrocephalus 41
7.1.3 Normal-Pressure Hydrocephalus 42
7.1.4 Ex-Vacuo Hydrocephalus 42
8 Hydrocephalus Market, by Diagnosis
8.1 Introduction 44
8.1.1 CT Scan–Head 45
8.1.2 MRI 45
8.1.3 Head Ultrasound 45
9 Hydrocephalus Market, by Treatment
9.1 Introduction 47
9.1.1 Surgery–Shunt Insertion 48
9.1.2 Ventriculostomy 48
9.1.3 Medication 48
10 Hydrocephalus Market, by End User
10.1 Introduction 51
10.1.1 Hospitals & Clinics 52
10.1.2 Diagnostic Centres 52
10.1.3 Academic Institutions and Research Organizations 52
11 Global Hydrocephalus Market, by Region
11.1 Introduction 54
11.2 Americas 55
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.2.1 North America 58
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.2.1.1 US 60
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.2.1.2 Canada 62
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.2.2 South America 63
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.3 Europe 66
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4 Western Europe 69
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.1 Germany 71
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.2 UK 73
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.3 France 75
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.4 Spain 76
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.5 Italy 78
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.6 Rest of Western Europe 80
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.4.7 Eastern Europe 81
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5 Asia-Pacific 84
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.1 China 86
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.2 Japan 88
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.3 India 90
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.4 Australia 91
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.5 South Korea 93
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.5.6 Rest of Asia-Pacific 95
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.6 Middle East & Africa 97
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.6.1 Middle East 99
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
11.6.2 Africa 101
Hydrocephalus Market, by Type
Hydrocephalus Market, by Diagnosis
Hydrocephalus Market, by Treatment
Hydrocephalus Market, by End User
12 Competitive Landscape
12.1 Competitive Scenario 104
12.1.1 Introduction 104
12.2 Company Market Share Analysis 105
12.2.1 Introduction 105
12.3 Key Developments 106
13 Company Profiles
13.1 DePuy Synthes 109
13.1.1 Company Overview 109
13.1.2 Financial Overview 109
13.1.3 Products Offered 110
13.1.4 Key Developments 110
13.1.5 SWOT Analysis 110
13.1.6 Key Strategies 110
13.2 Boston Neurosciences 111
13.2.1 Company Overview 111
13.2.2 Financial Overview 111
13.2.3 Products Offered 111
13.2.4 Key Developments 111
13.2.5 SWOT Analysis 111
13.2.6 Key Strategies 111
13.3 Medtronic Plc 112
13.3.1 Company Overview 112
13.3.2 Financial Overview 112
13.3.3 Products Offered 113
13.3.4 Key Developments 113
13.3.5 SWOT Analysis 113
13.3.6 Key Strategies 114
13.4 Integra LifeSciences Corporation 115
13.4.1 Company Overview 115
13.4.2 Financial Overview 115
13.4.3 Products Offered 116
13.4.4 Key Developments 117
13.4.5 SWOT Analysis 118
13.4.6 Key Strategies 118
13.5 Spiegelberg GmbH & Co. KG 119
13.5.1 Company Overview 119
13.5.2 Financial Overview 119
13.5.3 Products Offered 119
13.5.4 Key Developments 119
13.5.5 SWOT Analysis 119
13.5.6 Key Strategies 120
13.6 RAUMEDIC Inc. 121
13.6.1 Company Overview 121
13.6.2 Financial Overview 121
13.6.3 Products Offered 121
13.6.4 Key Developments 121
13.6.5 SWOT Analysis 121
13.6.6 Key Strategies 121
13.7 Sophysa SA 122
13.7.1 Company Overview 122
13.7.2 Financial Overview 122
13.7.3 Products Offered 122
13.7.4 Key Developments 122
13.7.5 SWOT Analysis 123
13.7.6 Key Strategies 123
13.8 Terumo Corporation 124
13.8.1 Company Overview 124
13.8.2 Financial Overview 124
13.8.3 Products Offered 125
13.8.4 Key Developments 125
13.8.5 SWOT Analysis 125
13.8.6 Key Strategies 125
13.9 Natus Medical Incorporated 126
13.9.1 Company Overview 126
13.9.2 Financial Overview 126
13.9.3 Products Offered 127
13.9.4 Key Developments 127
13.9.5 SWOT Analysis 127
13.9.6 Key Strategies 127
13.10 Johnson & Johnson Services Inc. 128
13.10.1 Company Overview 128
13.10.2 Financial Overview 128
13.10.3 Products Offered 129
13.10.4 Key Developments 129
13.10.5 SWOT Analysis 129
13.10.6 Key Strategies 130
13.11 B. Braun Melsungen AG 131
13.11.1 Company Overview 131
13.11.2 Financial Overview 131
13.11.3 1.10.3 Products Offered 132
13.11.4 Key Developments 132
13.11.5 SWOT Analysis 132
13.11.6 1.10.6 Key Strategies 132
13.12 Christoph Miethke GmbH & Co. KG 133
13.12.1 Company Overview 133
13.12.2 Financial Overview 133
13.12.3 Products Offered 133
13.12.4 Key Developments 133
13.12.5 SWOT Analysis 133
13.12.6 Key Strategies 133
13.13 Tokibo Co., Ltd. 134
13.13.1 Company Overview 134
13.13.2 Financial Overview 134
13.13.3 Products Offered 134
13.13.4 Key Developments 134
13.13.5 SWOT Analysis 134
13.13.6 Key Strategies 134
13.14 HLL Lifecare Limited 135
13.14.1 Company Overview 135
13.14.2 Financial Overview 135
13.14.3 Products Offered 135
13.14.4 Key Developments 135
13.14.5 SWOT Analysis 135
13.14.6 Key Strategies 135
14 Appendix
14.1 Discussion Blue Print 137
15 List of Tables
TABLE 1 MARKET SYNOPSIS 18
TABLE 2 LIST OF ASSUMPTIONS 21
TABLE 3 GLOBAL HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 40
TABLE 4 GLOBAL HYDROCEPHALUS MARKET FOR CONGENITAL HYDROCEPHALUS, BY REGION 2020–2027 (USD MILLION) 41
TABLE 5 GLOBAL HYDROCEPHALUS MARKET FOR ACQUIRED HYDROCEPHALUS, BY REGION 2020–2027 (USD MILLION) 41
TABLE 6 GLOBAL HYDROCEPHALUS MARKET FOR NORMAL-PRESSURE HYDROCEPHALUS, BY REGION 2020–2027 (USD MILLION) 42
TABLE 7 GLOBAL HYDROCEPHALUS MARKET FOR EX-VACUO HYDROCEPHALUS, BY REGION 2020–2027 (USD MILLION) 42
TABLE 8 GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 44
TABLE 9 GLOBAL HYDROCEPHALUS MARKET, FOR CT SCAN–HEAD BY REGION 2020–2027 (USD MILLION) 45
TABLE 10 GLOBAL HYDROCEPHALUS MARKET, FOR MRI BY REGION 2020–2027 (USD MILLION) 45
TABLE 11 GLOBAL HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY REGION 2020–2027 (USD MILLION) 45
TABLE 12 GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT2020–2027 (USD MILLION) 47
TABLE 13 GLOBAL HYDROCEPHALUS MARKET, FOR SURGERY–SHUNT INSERTION BY REGION, 2020–2027 (USD MILLION) 48
TABLE 14 GLOBAL HYDROCEPHALUS MARKET, FOR VENTRICULOSTOMY BY REGION, 2020–2027 (USD MILLION) 48
TABLE 15 GLOBAL HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 48
TABLE 16 GLOBAL HYDROCEPHALUS MARKET, FOR MEDICATION BY REGION, 2020–2027 (USD MILLION) 49
TABLE 17 GLOBAL HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 51
TABLE 18 GLOBAL HYDROCEPHALUS MARKET FOR HOSPITALS & CLINICS, BY REGION 2020–2027 (USD MILLION) 52
TABLE 19 GLOBAL HYDROCEPHALUS MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 52
TABLE 20 GLOBAL HYDROCEPHALUS MARKET FOR ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS, BY REGION 2020–2027 (USD MILLION) 52
TABLE 21 GLOBAL HYDROCEPHALUS MARKET, BY REGION 2020–2027 (USD MILLION) 54
TABLE 22 AMERICAS HYDROCEPHALUS MARKET, BY REGION 2020–2027 (USD MILLION) 55
TABLE 23 AMERICAS HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 56
TABLE 24 AMERICAS HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 56
TABLE 25 AMERICAS HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 56
TABLE 26 AMERICAS HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 57
TABLE 27 AMERICAS HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 57
TABLE 28 NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 58
TABLE 29 NORTH AMERICA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 58
TABLE 30 NORTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 59
TABLE 31 NORTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 59
TABLE 32 NORTH AMERICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 33 NORTH AMERICA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 60
TABLE 34 US HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 60
TABLE 35 US HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 60
TABLE 36 US HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 61
TABLE 37 US HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 38 US HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 61
TABLE 39 CANADA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 40 CANADA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 62
TABLE 41 CANADA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 62
TABLE 42 CANADA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 43 CANADA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 63
TABLE 44 SOUTH AMERICA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 63
TABLE 45 SOUTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 64
TABLE 46 SOUTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 64
TABLE 47 SOUTH AMERICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 48 SOUTH AMERICA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 65
TABLE 49 EUROPE HYDROCEPHALUS MARKET, BY REGION 2020–2027 (USD MILLION) 66
TABLE 50 EUROPE HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 66
TABLE 51 EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 67
TABLE 52 EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 67
TABLE 53 EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 67
TABLE 54 EUROPE HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 68
TABLE 55 WESTERN EUROPE HYDROCEPHALUS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 69
TABLE 56 WESTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 70
TABLE 57 WESTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 70
TABLE 58 WESTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 70
TABLE 59 WESTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 71
TABLE 60 WESTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 71
TABLE 61 GERMANY HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 71
TABLE 62 GERMANY HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 72
TABLE 63 GERMANY HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 72
TABLE 64 GERMANY HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 65 GERMANY HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 73
TABLE 66 UK HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 73
TABLE 67 UK HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 73
TABLE 68 UK HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 74
TABLE 69 UK HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 70 UK HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 74
TABLE 71 FRANCE HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 75
TABLE 72 FRANCE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 75
TABLE 73 FRANCE HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 75
TABLE 74 FRANCE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 76
TABLE 75 FRANCE HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 76
TABLE 76 SPAIN HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 76
TABLE 77 SPAIN HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 77
TABLE 78 SPAIN HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 77
TABLE 79 SPAIN HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 80 SPAIN HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 78
TABLE 81 ITALY HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 78
TABLE 82 ITALY HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 78
TABLE 83 ITALY HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 79
TABLE 84 ITALY HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 85 ITALY HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 79
TABLE 86 . REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 80
TABLE 87 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 80
TABLE 88 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 80
TABLE 89 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 90 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 81
TABLE 91 EASTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 81
TABLE 92 EASTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 82
TABLE 93 EASTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 82
TABLE 94 EASTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 95 EASTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 83
TABLE 96 ASIA PACFIC HYDROCEPHALUS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 84
TABLE 97 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 85
TABLE 98 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 85
TABLE 99 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 85
TABLE 100 ASIA-PACIFIC HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 101 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 86
TABLE 102 CHINA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 86
TABLE 103 CHINA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 87
TABLE 104 CHINA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 87
TABLE 105 CHINA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 106 CHINA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 88
TABLE 107 JAPAN HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 88
TABLE 108 JAPAN HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 88
TABLE 109 JAPAN HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 89
TABLE 110 JAPAN HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 111 JAPAN HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 89
TABLE 112 INDIA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 90
TABLE 113 INDIA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 90
TABLE 114 INDIA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 90
TABLE 115 INDIA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 116 INDIA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 91
TABLE 117 AUSTRALIA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 118 AUSTRALIA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 92
TABLE 119 AUSTRALIA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 92
TABLE 120 AUSTRALIA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 121 AUSTRALIA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 93
TABLE 122 SOUTH KOREA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 93
TABLE 123 SOUTH KOREA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 93
TABLE 124 SOUTH KOREA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 94
TABLE 125 SOUTH KOREA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 126 SOUTH KOREA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 94
TABLE 127 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 95
TABLE 128 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 95
TABLE 129 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 95
TABLE 130 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 131 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 96
TABLE 132 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY REGION 2020–2027 (USD MILLION) 97
TABLE 133 MIDDLE EAST & AFRICA MERICAS HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 97
TABLE 134 MIDDLE EAST & AFRICA MERICAS HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 98
TABLE 135 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 98
TABLE 136 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 137 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 99
TABLE 138 MIDDLE EAST HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 99
TABLE 139 MIDDLE EAST HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 99
TABLE 140 MIDDLE EAST HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 100
TABLE 141 MIDDLE EAST HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 142 MIDDLE EAST HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 100
TABLE 143 AFRICA HYDROCEPHALUS MARKET, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 144 AFRICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020–2027 (USD MILLION) 101
TABLE 145 AFRICA HYDROCEPHALUS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 101
TABLE 146 AFRICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 147 AFRICA HYDROCEPHALUS MARKET, BY END USER 2020–2027 (USD MILLION) 102
TABLE 148 GLOBAL HYDROCEPHALUS MARKET: KEY DEVELOPMENT 106
16 List of Figures
FIGURE 1 GLOBAL HYDROCEPHALUS MARKET: MARKET STRUCTURE 21
FIGURE 2 RESEARCH PROCESS OF MRFR 23
FIGURE 3 TOP-DOWN AND BOTTOM-UP APPROACH 26
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL HYDROCEPHALUS MARKET 35
FIGURE 5 VALUE CHAIN: GLOBAL HYDROCEPHALUS MARKET 37
FIGURE 6 GLOBAL HYDROCEPHALUS MARKET, BY TYPE 2020 & 2027 (USD MILLION) 41
FIGURE 7 GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS 2020 & 2027 (USD MILLION) 44
FIGURE 8 GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT 2020 & 2027 (USD MILLION) 47
FIGURE 9 GLOBAL HYDROCEPHALUS MARKET, BY END USER 2020 & 2027 (USD MILLION) 51
FIGURE 10 GLOBAL HYDROCEPHALUS MARKET, BY REGION 2020 & 2027 (USD MILLION) 54
FIGURE 11 AMERICAS HYDROCEPHALUS MARKET, BY REGION COUNTRY 2020 (%) 55
FIGURE 12 NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY 2020 (%) 58
FIGURE 13 EUROPE HYDROCEPHALUS MARKET, BY REGION 2020 (%) 66
FIGURE 14 WESTERN EUROPE HYDROCEPHALUS MARKET, BY COUNTRY 2020 (%) 69
FIGURE 15 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY COUNTRY 2020 & 2027 (USD MILLION) 84
FIGURE 16 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY COUNTRY 2020 (%) 97
FIGURE 17 GLOBAL HYDROCEPHALUS MARKET COMPETITIVE LANDSCAPE (%) 104
FIGURE 18 GLOBAL HYDROCEPHALUS MARKET, MARKET SHARE ANALYSIS 2020 (%) 105
Global Hydrocephalus Market: Competitive Landscape
The prominent players in the global hydrocephalus market are Medtronic Plc (PS Medical), Codman (Johnson & Johnson), Integra LifeSciences Corporation, B. Braun Melsungen AG, DePuy Synthes, Christoph Miethke GmbH & Co. KG, Spiegelberg GmbH & Co. KG and others.
Medtronic Plc (PS Medical) is the holds the largest share for the global hydrocephalus market in 2017. The company is a global healthcare solutions company committed to improving the lives of people through medical technologies, services, and solutions. Medtronic Plc with Covidien has accelerated and advanced its ability to create meaningful innovations for hospitals, health systems, and healthcare providers so that it can deliver the best care possible to patients and their families around the world.
Codman (Johnson & Johnson) holds second position in terms of market share in the global hydrocephalus market in 2017. The company manufactures medical devices for various specialties, such as orthopedics, cardiovascular diseases, and many others. J&J Services has acquired and merged with various other companies to expand its portfolio of endoscopic devices. Ethicon, a subsidiary of J&J offers a broad range of suture needle products
Integra LifeSciences Corporation holds third position in terms of market share in the global hydrocephalus market in 2017. The company is an international leader in medical technology. The key focus of the company is to provide patients with a high level of satisfaction. The company also provides and operates innovative solutions in the field of orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. In the US, Integra LifeSciences Corporation is one of the leading players for providing surgical devices and instruments to various hospitals, surgery centers, physicians, and dental offices.
- Braun Melsungen AG is a leading healthcare supplier. The company provides its products for hospitals, surgeries, private practices (medical care and doctors´ offices), and extracorporeal blood treatments. The company’s product segments include clinical nutrition, urinary care, infection prevention, infusion therapy, diabetes care, neurosurgery, extracorporeal blood treatment, IV drugs, orthopedics, spine, and wound care, among others. The company operates in four major divisions, namely, hospital care, Aesculap, outpatient market, and B. Braun Avitum. With these four divisions, the company has a wide range of products with about 5,000 products, out of which 95% of the products are manufactured by the company. Geographically the company operates in 64 countries in regions such as Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
DePuy Synthes is a contract manufacturing organization of softgel capsules and supplies to the nutritional supplement market. It operates a Good Manufacturing Practices (GMP) facility licensed by the UK Medicines & Healthcare products Regulatory Authority (MHRA). EuroCaps is a part of DCC Health and Beauty Solutions, a subsidiary of DCC Healthcare.
Medtronic Plc (PS Medical), and Codman (Johnson & Johnson) are the major companies for hydrocephalus operating on a global scale. The lower market share of Spiegelberg GmbH & Co. KG can be attributed to fewer products offering, as compared to other major players. Key players such as Christoph Miethke GmbH & Co. KG, RAUMEDIC Inc., Natus Medical Incorporated, Terumo Corporation, Boston Neurosciences increase the level of competition in the global hydrocephalus market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.